JOHN CARR: Open Payments
NPI 1013643873 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$580 in 23 payments from 9 companies in 2025. Trend: 2023 $549 · 2024 $258 · 2025 $580
Food & beverage: $580
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $146 |
| Neurocrine BioSciences, Inc. | 5 | $121 |
| Teva Pharmaceuticals USA, Inc. | 5 | $107 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| ABBVIE INC. | 3 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Corium, LLC | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: SPRAVATO, INGREZZA, AUSTEDO XR, REXULTI, CAPLYTA, VRAYLAR, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across ID — which companies pay providers there.
